Challenge Theme – AAV

Filter:AllGeneralRegulatory NewsNewsletterExternalManufacturingPress ReleaseSkills and TrainingChallenge Theme – PATChallenge Theme – AAVChallenge Theme – iPSCsNon ClinicalCommercialisation of Research
Year:All2024202320222021 →
CGT Catapult, Pharmaron Biologics (UK) Ltd and Complement Therapeutics receive £1.4m grant to develop a perfusion process to improve production of gene therapiesCGT Catapult, Pharmaron Biologics (UK) Ltd and Complement Therapeutics receive £1.4m grant to develop a perfusion process to improve production of gene therapiesCGT Catapult establishes consortium to improve AAV formulationCGT Catapult establishes consortium to improve AAV formulationChallenge Theme R&D spotlight: Development of an end-to-end scalable AAV platformChallenge Theme R&D spotlight: Development of an end-to-end scalable AAV platformTouchlight, Cell and Gene Therapy Catapult and Complement Therapeutics to develop innovative manufacturing process for gene therapiesTouchlight, Cell and Gene Therapy Catapult and Complement Therapeutics to develop innovative manufacturing process for gene therapiesCell and Gene Therapy Catapult, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapiesCell and Gene Therapy Catapult, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapiesPress Release: AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and ControlPress Release: AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and ControlPress release: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsyPress release: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy